Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 63Carcinoma, Hepatocellular 55Lung Neoplasms 32Breast Neoplasms 29Small Cell Lung Carcinoma 23Neoplasms 21Triple Negative Breast Neoplasms 18Neoplasm Metastasis 17Urinary Bladder Neoplasms 15Carcinoma, Transitional Cell 15Melanoma 14Colorectal Neoplasms 14Glioblastoma 10Prostatic Neoplasms 9Ovarian Neoplasms 9Head and Neck Neoplasms 9Recurrence 8Liver Neoplasms 8Endometrial Neoplasms 8Carcinoma, Renal Cell 8Mesothelioma, Malignant 7Uterine Cervical Neoplasms 6Sarcoma 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Rectal Neoplasms 5Kidney Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Squamous Cell 5Pancreatic Neoplasms 4

Interventions

Surveys and Questionnaires 6Methods 6Radiotherapy 5Cisplatin 5pembrolizumab 4durvalumab 3Sentinel Lymph Node Biopsy 3Radiosurgery 3Palliative Care 3Indocyanine Green 3Early Intervention, Educational 3Brachytherapy 3Bleomycin 3tremelimumab 2aldesleukin 2Surgical Procedures, Operative 2Radiation 2Paclitaxel 2Interviews as Topic 2Immunoglobulin G 2Imiquimod 2Gemcitabine 2Electrochemotherapy 2Drug Therapy 2Disulfides 2Dehydroepiandrosterone 2Counseling 2Carboplatin 2Biopsy 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Vulvar Neoplasms × atezolizumab × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡